WO2019174610A1 - Virus oncolytique, séquence d'adn synthétique et utilisation associée - Google Patents

Virus oncolytique, séquence d'adn synthétique et utilisation associée Download PDF

Info

Publication number
WO2019174610A1
WO2019174610A1 PCT/CN2019/078117 CN2019078117W WO2019174610A1 WO 2019174610 A1 WO2019174610 A1 WO 2019174610A1 CN 2019078117 W CN2019078117 W CN 2019078117W WO 2019174610 A1 WO2019174610 A1 WO 2019174610A1
Authority
WO
WIPO (PCT)
Prior art keywords
lys
arg
oncolytic virus
trp
cys
Prior art date
Application number
PCT/CN2019/078117
Other languages
English (en)
Chinese (zh)
Inventor
蔡立刚
Original Assignee
蔡立刚
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 蔡立刚 filed Critical 蔡立刚
Priority to CN201980003419.3A priority Critical patent/CN111094324B/zh
Publication of WO2019174610A1 publication Critical patent/WO2019174610A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/145—Rhabdoviridae, e.g. rabies virus, Duvenhage virus, Mokola virus or vesicular stomatitis virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un virus oncolytique, une séquence d'ADN synthétique et une utilisation associée. La séquence d'expression d'un peptide de base exogène est insérée dans le génome du virus oncolytique, et le peptide basique est exprimé dans un processus physiologique, de telle sorte que la valeur du pH du milieu hôte infecté par celui-ci est augmentée. La séquence d'ADN synthétique est utilisée pour exprimer un peptide basique, la teneur en acide aminé basique dans le peptide basique dépassant 60 %. Le virus oncolytique et la séquence d'ADN synthétique fournis par l'invention sont appliqués dans la préparation d'un médicament antitumoral et ont un bon effet antitumoral.
PCT/CN2019/078117 2018-03-14 2019-03-14 Virus oncolytique, séquence d'adn synthétique et utilisation associée WO2019174610A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201980003419.3A CN111094324B (zh) 2018-03-14 2019-03-14 一种溶瘤病毒、合成dna序列及其应用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862643166P 2018-03-14 2018-03-14
US62/643,166 2018-03-14

Publications (1)

Publication Number Publication Date
WO2019174610A1 true WO2019174610A1 (fr) 2019-09-19

Family

ID=67908669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/078117 WO2019174610A1 (fr) 2018-03-14 2019-03-14 Virus oncolytique, séquence d'adn synthétique et utilisation associée

Country Status (2)

Country Link
CN (1) CN111094324B (fr)
WO (1) WO2019174610A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112538466A (zh) * 2020-12-10 2021-03-23 武汉博威德生物技术有限公司 一种柯萨奇病毒及其在制备抗肝癌药物中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005074968A2 (fr) * 2004-02-10 2005-08-18 Universiteit Maastricht Utilisation medicale de peptides basiques
WO2011100688A1 (fr) * 2010-02-12 2011-08-18 Dana-Farber Cancer Institute, Inc. Antagonistes améliorés du muc1
WO2013110120A1 (fr) * 2012-01-24 2013-08-01 Inter-K Pty Limited Agents peptidiques utilisés en thérapie anticancéreuse
US20160008480A1 (en) * 2014-07-08 2016-01-14 Samsung Electronics Co., Ltd. Fusion protein comprising targeting moiety, cleavage site, and cell membrane penetrating domain, and use thereof
WO2018027316A1 (fr) * 2016-08-09 2018-02-15 Alkayyal Almohanad Rhabdovirus oncolytique exprimant il12

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008140621A2 (fr) * 2006-12-21 2008-11-20 Mount Sinai School Of Medicine Of New York University Virus oncolytiques transgéniques et leurs utilisations
KR100931863B1 (ko) * 2007-09-04 2009-12-15 가톨릭대학교 산학협력단 약독화된 콕사키바이러스게놈을 이용한 외래 유전자 발현시스템
EP2085092A1 (fr) * 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Paramyxovirus oncolytiques atténués encodant des cytokines aviaires
ES2385251B1 (es) * 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
US20130323205A1 (en) * 2010-09-24 2013-12-05 Oncos Therapeutics Oy Oncolytic adenoviral vectors and methods and uses related thereto
CN103981152B (zh) * 2014-04-16 2015-01-21 武汉博威德生物技术有限公司 一种柯萨奇病毒及其制备抗肿瘤药物之应用
CN104151402B (zh) * 2014-08-06 2017-01-18 苏州大学 病毒性心肌炎环肽疫苗及其制备方法
CN106632613B (zh) * 2017-01-17 2020-07-31 中国药科大学 与柯萨奇病毒腺病毒受体相关的亲和肽
CN107164338A (zh) * 2017-06-27 2017-09-15 镇江市卫克生物科技有限公司 一种重组溶瘤病毒及其应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005074968A2 (fr) * 2004-02-10 2005-08-18 Universiteit Maastricht Utilisation medicale de peptides basiques
WO2011100688A1 (fr) * 2010-02-12 2011-08-18 Dana-Farber Cancer Institute, Inc. Antagonistes améliorés du muc1
WO2013110120A1 (fr) * 2012-01-24 2013-08-01 Inter-K Pty Limited Agents peptidiques utilisés en thérapie anticancéreuse
US20160008480A1 (en) * 2014-07-08 2016-01-14 Samsung Electronics Co., Ltd. Fusion protein comprising targeting moiety, cleavage site, and cell membrane penetrating domain, and use thereof
WO2018027316A1 (fr) * 2016-08-09 2018-02-15 Alkayyal Almohanad Rhabdovirus oncolytique exprimant il12

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
POST, D. E.: "Cancer Therapy with a Replicating Oncolytic Adenovirus Targeting the Hypoxic Microenvironment of Tumors", CLINICAL CANCER RESEARCH, vol. 10, no. 24, 15 December 2004 (2004-12-15), pages 8603 - 8612, XP055637037 *

Also Published As

Publication number Publication date
CN111094324B (zh) 2023-10-10
CN111094324A (zh) 2020-05-01

Similar Documents

Publication Publication Date Title
ES2878549T3 (es) Adenovirus oncolítico para su uso en el tratamiento del cáncer cerebral
JP2013213058A (ja) ウイルスを用いた新生物の処置
JP5807788B2 (ja) ニューカッスル病ウイルスの新規クローン、その作製及び癌治療への応用
CN109414487B (zh) 利用stat1/3抑制剂与溶瘤型疱疹病毒的组合物和方法
CN111315873A (zh) 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
US20220288142A1 (en) Recombinant oncolytic virus, synthetic dna sequence, and application thereof
Carter et al. Clinical trials of oncolytic viruses in breast cancer
JP2020528890A (ja) 腫瘍を治療するためのウイルス
WO2019174610A1 (fr) Virus oncolytique, séquence d'adn synthétique et utilisation associée
JP2002515442A (ja) 癌を処置するためのアデノウィルス−化学治療剤のコンビネーション
CN111939262B (zh) 一种治疗肿瘤或癌症的药物组合物和其应用
WO2022033469A1 (fr) Virus oncolytique recombinant, son procédé de construction et son utilisation
WO2018213412A1 (fr) Virus oncolytique recombinant
US20220267799A1 (en) Genetically modified enterovirus vectors
WO2019201192A1 (fr) Virus coxsackie b pour le traitement de tumeurs
WO2019144874A1 (fr) Application d'une souche atténuée de virus zika (zikv) dans le traitement d'un gliome cérébral
CN108495934B (zh) 将腺病毒和化学治疗剂组合用于治疗癌症
JP2022520220A (ja) 組換えワクシニアウイルスおよびその使用方法
US20190284538A1 (en) Recombinant oncolytic virus, synthetic dna sequence, and application thereof
WO2022033467A1 (fr) Procédé de construction d'un virus oncolytique
CN110564700A (zh) 携带鲎凝集素基因的溶瘤痘苗病毒、构建方法及应用
CN107536845A (zh) 一种防治肿瘤的药物及其用途
Rasoul The Anti-cancer Impact of Genetically Engineered Newcastle Disease Virus Expressing GFP Gene Against U87-MG Cell Line
CN117695391A (zh) 一种携带萤火虫荧光素酶基因的溶瘤痘苗病毒负载光敏剂Ce6的复合物、制备方法及应用
TW202409286A (zh) 基因組穩定性增強之基因改造腸病毒載體

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19766512

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19766512

Country of ref document: EP

Kind code of ref document: A1